Opinion statement
Although 60% of those diagnosed with non-small-cell lung cancer are 60 years of age or older, the elderly are often undertreated. Furthermore, those older than age 70 are under-represented in clinical research trials. Tremendous bias exists against treating the elderly; therapeutic nihilism and constrained societal/financial resources conspire to maintain the status quo. In limited stage small cell carcinoma of the lung (SCLC), a pivotal meta-analysis by Pignon et al. showed no obvious benefit for chemoradiation over chemotherapy alone in patients older than 70 years of age. However, more recent trials have revealed a clear-cut benefit for fit elderly patients to receive combined modality therapy versus chemotherapy alone, even though outcome generally remains superior for younger patients. For patients with locally advanced non-small-cell lung cancer, conflicting results exist. Individual trials evaluating combined modality therapy have shown no impairment in survival for older patients, but retrospective analyses of the Radiation Therapy Oncology Group database have demonstrated that increased therapeutic intensity does not translate into improved outcome compared with standard, single daily fraction radiation alone. Weighted survival analyses that deduct time spent with progressive disease or significant toxicity have reinforced this notion. In advanced non-small-cell lung cancer, fit elderly patients who receive platinum-based regimens do as well, or nearly as well, as patients younger than age 70, although the incidence of neutropenia and fatigue is often higher. Platinum doses above 75 mg/m2 every 3 weeks to 4 weeks are relatively more toxic in the elderly than are lower doses. Three separate studies from Italy have formally assessed the elderly. One showed superiority for single-agent vinorelbine versus best supportive care regarding survival rates and quality of life. A second showed a marked survival advantage for combination vinorelbine and gemcitabine versus vinorelbine alone. However, a much larger, more credible study demonstrated no benefit for combination vinorelbine and gemcitabine versus the constituent single agents. To date, no elderly-specific trials have addressed the role of taxanes or of platinum-based combination therapy versus non-platinum monotherapy or doublets. Comprehensive evaluation of comorbidities and their influence on outcome have not been conducted, and there are virtually no data for patients older than age 80.
Similar content being viewed by others
References and Recommended Reading
Kennedy BJ: Specific considerations for older patients with cancer. In Medical Oncology. Edited by Calabresi PE, Shine PS. New York: McGraw Hill; 1993:1219–1230.
Yancik R, Reis LA: Aging in cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000, 14:17–23.
Jara C, Gomez-Aldaravi JL, Tirado R, et al.: Small-cell lung cancer in the elderly: is age of patient a relative issue? Acta Oncol 1999, 38:781–786.
Tamura M, Ueoka H, Kiura K, et al.: Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Group trials. Acta Med Okayama 1998, 52:105–111.
Johnson DH: Treatment of the elderly patient with small-cell lung cancer. Chest 1993, 103(Suppl 1):72S-74S.
Shepherd F, Goss P, Evans W, et al.: Treatment of small-cell lung cancer in the elderly. Proc Am Soc Clin Oncol 1991, 10:241.
Findley MPN, Griffin AM, Raghavan D, et al.: Retrospective review of chemotherapy for small-cell lung cancer in the elderly: does the end justify the means? Eur J Cancer 1991, 27:1597–1601.
Souhami RL, Spiro SG, Rudd PM, et al.: Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997, 89:577–580.
Medical Research Council Lung Cancer Working Party: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomized trial. Lancet 1996, 348:563–566.
Clark PI, Cottier B, Joel SP, et al.: Two prolonged schedules of single-agent oral etoposide of differing duration and dose in patients with untreated small-cell lung cancer. Proc Am Soc Clin Oncol 1991, 10:268.
Westeel V, Murray N, Gelmon K, et al.: New combination of old drugs for elderly patients with small cell lung cancer: A Phase II study of the PAVE regimen,. J Clin Oncol 1998; May; 16 (5):1940–7.
Pignon JP, Arriagada R, Ihde D, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992, 327:1618. Influential meta-analysis that confirmed the primacy of combined modality therapy in limited small-cell lung cancer versus chemotherapy alone. This benefit was confined to patients younger than age 70, which has deterred many investigators from offering aggressive therapy to the elderly.
Yuen AR, Zou G, Turrisi AT, et al.: Similar outcome of elderly patients on Intragroup Trial 0096: cisplatin, etoposide and thoracic radiotherapy administered once or twice daily in limited stage lung cancer. Cancer 2000, 89:1953–1960. Retrospective analysis of a pivotal Phase III trial in limited small-cell lung cancer that showed that the elderly benefit from combined modality therapy, albeit not as broadly as younger patients do.
Werner-Wasik M, Scott C, Cox JD: Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000, 48:1475–1482.
Sause WT, Scott CB, Taylor SGN, et al.: RTOG 88-08 and ECOG 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995, 37:198–205.
Sause WT, Kolesar P, Taylor SG, et al.: Five-year results: phase III trial of regionally advanced unresectable non-small-cell lung cancer, RTOG 88-08, ECOG 4588, SWOG 8992. Proc Am Soc Clin Oncol 1998, 17: A-1743.
Langer C, Scott C, Byhardt R, et al.: Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LANSCLC). Lung Cancer 2000, 29(Suppl 1):104.
Mosvas B, Scott C, Sause W, et al.: The benefit of treatment intensification is age and histology dependent in patients with locally advanced non-small-cell lung carcinoma (NSCLC): a quality adjusted survival analysis of the Radiation Therapy Oncology Group chemoradiation studies. Int J Rad Onc Biol Phys 1999, 45:1143–1149. One of the very few quality-of-life analyses of elderly patients who receive combined modality therapy for LA-NSCLC.
Langer CJ, Hsu C, Curran W, et al.: Do elderly patients with locally advanced non-small-cell lung cancer (NSCLC) benefit from combined modality therapy? A secondary analysis of RTOG 94-10. Paper presented at the ASTRO 43rd Annual Meeting, San Francisco, 2001.
Rocha Lima CMS, Herndon JE, II, Kosty M, et al.: Therapy choices among older patients with lung cancer: evaluation of two trials of the Cancer and Leukemia Group B. Cancer Submitted.
Ricci S, Antuzzo A, Galli L, et al.: Gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a multicenter Phase II study. Lung Cancer 2000, 27:75–80.
The Elderly Lung Cancer Vinorelbine Italian Study Group (ELVIS): Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91:66–72. Critical study that established the superiority of vinorelbine to best supportive care in elderly patients with advanced non-small-cell lung cancer.
Frasci G, Lorusso V, Panza N, et al.: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000, 18:2529–2536.
Gridelli C, Perrone F, Cigolari S, et al.: The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase III trial: gemcitabine and vinorelbine vs. vinorelbine vs. gemcitabine in elderly advanced NSCLC patients. Proc Am Soc Clin Oncol. 2001, 20:A-1230. Largest randomized trial performed to date in the elderly with advanced non-small-cell lung cancer. No advantage was observed for a non-platinum combination versus its constituent single agents.
Nguyen B, Sandler A, Denham C, et al.: The safety and efficacy of gemcitabine plus cisplatin in elderly chemo-naive SCLC patients (age < 70 years) as compared to those with age < 70 years. Proc Am Soc Clin Oncol 1999, 18:A-1818.
Martins SJ, Pereira JR, Ikari FK, et al.: Chemotherapy with cisplatin and vinorelbine for elderly NSCLC patients. Proc Am Soc Clin Oncol 1999, 18:A-1804.
Langer CJ, Manola J, Bernardo P, et al.: Advanced age alone does NOT compromise outcome in fit non-small-cell lung cancer (NSCLC) patients receiving platinum (DDP) based therapy: therapeutic implications of ECOG 5592. Proc Am Soc Clin Oncol 2000, 19:A-1912. Elderly patients who were and fit and who received platinumbased therapy experienced more leukopenia and neuropsychiatric toxicity compared with younger patients, but there was no difference in response rate, time to progression, survival, or quality of life in either age cohort.
Kelly K, Giarritta S, Hayes S, et al.: Should older patients receive combination chemotherapy for advanced non-small-cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001, 21:A-1313.
Rosvold E, Langer CJ, McAleer C, et al.: Advancing age does not exacerbate toxicity or compromise outcome in NSCLC patients receiving paclitaxel/carboplatin. Proc Am Soc Clin Oncol 1999, 18:A-1846.
Hensing TA, Socinski MA, Schell MJ, et al.: Age does not alter toxicity or survival for patients with stage IIIB/IV NSCLC treated with carboplatin and paclitaxel. Proc Am Soc Clin Oncol 2001, 20:A-1382.
Calvert AH, Newell DR, Gumrell LA, et al.: Carboplatin dose: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748–1756.
Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31–41.
Tucker MA, Murray N, Shaw EG, et al.: Second primary cancers related to smoking and treatment of small-cell lung cancer. J Natl Cancer Inst 1997, 89:1782.
VanHazel GZ, Scott M, Eagen RT: The effect of CNS metastasis on the survival of patients with small-cell cancer of the lung. Cancer 1983, 51:933–937.
Carmichael J, Crane JM, Bunn PA, et al.: Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 1988, 14:455–459.
Kosimidis PA, Mylonakis N, Skarlos D, et al.: A multicenter randomized trial of paclitaxel (175 mg/m2) plus carboplatin (AUC 6) versus paclitaxel (225 mg/m2) plus carboplatin (AUC 6) in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999, 18:463a.
Ramsey SD, Moinpour CM, Lovato LC, et al.: An economic analysis of Southwest Oncology Group Trial S9509: cisplatin/vinorelbine vs carboplatin/paclitaxel for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2000, 19:489a.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Langer, C.J. Elderly patients with lung cancer: Biases and evidence. Curr. Treat. Options in Oncol. 3, 85–102 (2002). https://doi.org/10.1007/s11864-002-0045-9
Issue Date:
DOI: https://doi.org/10.1007/s11864-002-0045-9